These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 25926405)

  • 21. Update on Emerging Infections: news from the Centers for Disease Control and Prevention. Update to the CDC’s Sexually Transmitted Diseases Treatment Guidelines, 2010: Oral cephalosporins no longer a recommended treatment for gonococcal infections .
    Maldonado NG; Takhar SS
    Ann Emerg Med; 2013 Jan; 61(1):91-5. PubMed ID: 23260686
    [No Abstract]   [Full Text] [Related]  

  • 22. Verified clinical failure with cefotaxime 1g for treatment of gonorrhoea in the Netherlands: a case report.
    van Dam AP; van Ogtrop ML; Golparian D; Mehrtens J; de Vries HJ; Unemo M
    Sex Transm Infect; 2014 Nov; 90(7):513-4. PubMed ID: 25114322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Non-viral sexually transmitted infections - Epidemiology, clinical manifestations, diagnostics and therapy : Part 1: Gonococci].
    Nenoff P; Manos A; Ehrhard I; Krüger C; Paasch U; Helmbold P; Handrick W
    Hautarzt; 2017 Jan; 68(1):43-49. PubMed ID: 27981386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CDC update on gonorrhea: expand treatment to limit resistance.
    Campos-Outcalt D
    J Fam Pract; 2011 Dec; 60(12):736-40. PubMed ID: 22163356
    [No Abstract]   [Full Text] [Related]  

  • 25. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults.
    Bignell C; Unemo M;
    Int J STD AIDS; 2013 Feb; 24(2):85-92. PubMed ID: 24400344
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Retrospective analysis of antimicrobial susceptibility trends (2000-2009) in Neisseria gonorrhoeae isolates from countries in Latin America and the Caribbean shows evolving resistance to ciprofloxacin, azithromycin and decreased susceptibility to ceftriaxone.
    Starnino S; ; Galarza P; Carvallo ME; Benzaken AS; Ballesteros AM; Cruz OM; Hernandez AL; Carbajal JL; Borthagaray G; Payares D; Dillon JA
    Sex Transm Dis; 2012 Oct; 39(10):813-21. PubMed ID: 23001269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Failure of azithromycin 2.0 g in the treatment of gonococcal urethritis caused by high-level resistance in California.
    Gose SO; Soge OO; Beebe JL; Nguyen D; Stoltey JE; Bauer HM
    Sex Transm Dis; 2015 May; 42(5):279-80. PubMed ID: 25868141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-Effectiveness of Dual Antimicrobial Therapy for Gonococcal Infections Among Men Who Have Sex With Men in the Netherlands.
    Xiridou M; Lugnér A; de Vries HJ; van Bergen JE; Götz HM; van Benthem BH; Wallinga J; van der Sande MA
    Sex Transm Dis; 2016 Sep; 43(9):542-8. PubMed ID: 27513379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Will targeting oropharyngeal gonorrhoea delay the further emergence of drug-resistant Neisseria gonorrhoeae strains?
    Lewis DA
    Sex Transm Infect; 2015 Jun; 91(4):234-7. PubMed ID: 25911525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection in the United Kingdom of the
    Eyre DW; Town K; Street T; Barker L; Sanderson N; Cole MJ; Mohammed H; Pitt R; Gobin M; Irish C; Gardiner D; Sedgwick J; Beck C; Saunders J; Turbitt D; Cook C; Phin N; Nathan B; Horner P; Fifer H
    Euro Surveill; 2019 Mar; 24(10):. PubMed ID: 30862336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gonorrhoea treatment position statement.
    Fifer H; Hughes G; Radcliffe K
    Sex Transm Infect; 2015 Aug; 91(5):307. PubMed ID: 26195472
    [No Abstract]   [Full Text] [Related]  

  • 32. An audit of pharyngeal gonorrhoea treatment in a public sexual health clinic in Adelaide, South Australia.
    Hustig A; Bell C; Waddell R
    Int J STD AIDS; 2013 May; 24(5):399-400. PubMed ID: 23970709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gentamicin versus ceftriaxone for the treatment of gonorrhoea (G-TOG trial): study protocol for a randomised trial.
    Brittain C; Childs M; Duley L; Harding J; Hepburn T; Meakin G; Montgomery AA; Tan W; Ross JD
    Trials; 2016 Nov; 17(1):558. PubMed ID: 27881151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic characterisation of Neisseria gonorrhoeae resistant to both ceftriaxone and azithromycin.
    Whiley DM; Jennison A; Pearson J; Lahra MM
    Lancet Infect Dis; 2018 Jul; 18(7):717-718. PubMed ID: 29976521
    [No Abstract]   [Full Text] [Related]  

  • 35. Neisseria gonorrhoeae and emerging resistance to extended spectrum cephalosporins.
    Tapsall JW
    Curr Opin Infect Dis; 2009 Feb; 22(1):87-91. PubMed ID: 19532086
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Azithromycin in gonorrhoea.
    Handsfield HH
    Int J STD AIDS; 1997 Jul; 8(7):472-3. PubMed ID: 9228599
    [No Abstract]   [Full Text] [Related]  

  • 37. New treatment options for infections caused by increasingly antimicrobial-resistant Neisseria gonorrhoeae.
    Lee H; Lee K; Chong Y
    Expert Rev Anti Infect Ther; 2016; 14(2):243-56. PubMed ID: 26690658
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Committee Opinion No. 645: Dual Therapy for Gonococcal Infections.
    Obstet Gynecol; 2016 May; 127(5):e95-9. PubMed ID: 27548425
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Neisseria gonorrhoeae: antimicrobial resistance and study of population dynamics. Situation in Barcelona in 2011].
    Serra-Pladevall J; Barberá-Gracia MJ; Roig-Carbajosa G; Juvé-Saumell R; Gonzalez-Lopez JJ; Bartolomé-Comas R; Andreu-Domingo A
    Enferm Infecc Microbiol Clin; 2013 Nov; 31(9):579-83. PubMed ID: 23623686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variation in adherence to the treatment guidelines for Neisseria gonorrhoeae by clinical practice setting, California, 2009 to 2011.
    Lechtenberg RJ; Samuel MC; Bernstein KT; Lahiff M; Olson N; Bauer HM
    Sex Transm Dis; 2014 May; 41(5):338-44. PubMed ID: 24722391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.